AC Immune SA (ACIU)
| Market Cap | 243.60M -30.2% |
| Revenue (ttm) | 21.67M -39.5% |
| Net Income | -53.41M |
| EPS | -0.53 |
| Shares Out | 99.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,886 |
| Open | 2.430 |
| Previous Close | 2.400 |
| Day's Range | 2.381 - 2.460 |
| 52-Week Range | 2.095 - 4.000 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 8.57 (+249.8%) |
| Est. Earnings | Nov 3, 2026 |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow A... [Read more]
Financial Performance
In 2025, AC Immune's revenue was 3.57 million, a decrease of -86.92% compared to the previous year's 27.31 million. Losses were -70.45 million, 38.4% more than in 2024.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ACIU stock is "Strong Buy." The 12-month stock price target is $8.57, which is an increase of 249.80% from the latest price.
News
AC Immune Transcript: Study result
ACI-7104.056 met Part 1 safety and immunogenicity goals, with antibodies detected in CSF across treated participants. Exploratory biomarker and clinical correlations were encouraging but require confirmation; plans include a larger Part 2 study and quarterly-dose extension.
AC Immune Press release: Study result
AC Immune issued a press release on September 23, 2026, disclosing material business information to investors.
AC Immune Slides: Study result
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
AC Immune announces Phase 2 trial of ACI-7104 met primary endpoints
AC Immune (ACIU) announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with ...
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear ant...
AC Immune Slides: Investor presentation
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on August 24, 2026.
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.
AC Immune receives fast track designation, clearance for ACI-7104 IND
AC Immune (ACIU) announced that it has received fast track designation and clearance of its investigational new drug, or IND, application from the FDA for its wholly owned anti-alpha-synuclein active…
AC Immune Earnings release: Q2 2026
AC Immune released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
AC Immune First Half 2026 Financial and Corporate Update
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances...
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical ...
AC Immune announces interim data from first three cohorts of ABATE trial
AC Immune (ACIU) announced interim data from the first three cohorts of 74 patients with prodromal Alzheimer’s disease in the Phase 1b/2 ABATE trial following 12 months of treatment with…
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three A...
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of P...
AC Immune Slides: Investor presentation
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
AC Immune presents new Phase 1 data on uptake of ACI-19626
AC Immune (ACIU) SA announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography tracer ACI-19626 showing increased uptake in the…
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients ...
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appoi...
AC Immune reports Q1 EPS (15c), consensus (14c)
Reports Q1 revenue $1.12M, consensus $263,230. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our…
AC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteer...
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 ...
AC Immune Earnings release: Q1 2026
AC Immune released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
AC Immune Slides: Investor presentation
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Leerink calls AC Immune- Eli Lilly Tau amendment ‘great news’
Leerink analyst Marc Goodman says AC Immune’s (ACIU) amendment of the collaboration agreement with Eli Lilly (LLY) for the Morphomer Tau program is “great news” and underscores the continued interest…